PhilipBurkeMilamMD

Dermatology • Nashville, TN

Dermatologist

Join to view full profile

Dr. Milam is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Milam's full profile

Already have an account?

Office
3601 The Vanderbilt Clinic
Nashville, TN 37232
Phone+1 615-322-3000

Education & Training

Ohio State University HospitalResidency, Dermatology, 2018 - 2021
Ohio State University Wexner Medical CenterFellowship, 2016 - 2018
University of Missouri-ColumbiaInternship, Internal Medicine, 2015 - 2016
East Tennessee State University James H. Quillen College of MedicineClass of 2015

Certifications & Licensure

TN State Medical License 2021 - 2025
OH State Medical License 2016 - 2022
MO State Medical License 2015 - 2016
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

Outstanding Teaching Award University Missouri, Dept of Internal Medicine, 2016

Clinical Trials

Psoriasis Longitudinal Assessment and Registry Start of enrollment: 2007 Jun 21
Active, not recruiting
A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum Start of enrollment: 2014 Jan 31
Completed
Phase 2
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus. Start of enrollment: 2014 Sep 16
Completed
Phase 2
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment Start of enrollment: 2014 Nov 03
Completed
Phase 3
The Corrona Psoriasis (PSO) Registry Start of enrollment: 2015 Apr 01
Enrolling by invitation
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis Start of enrollment: 2016 Jun 22
Completed
Phase 3
Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) Start of enrollment: 2016 Oct 20
Completed
Phase 2
Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis Start of enrollment: 2017 Mar 28
Completed
Phase 3
An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum Start of enrollment: 2017 May 04
Completed
Phase 2
The Ohio State University Dermatology Biorepository Start of enrollment: 2017 Apr 19
Recruiting
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD) Start of enrollment: 2017 Nov 17
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

3 citations
Development of a Skin-Directed Scoring System for Stevens-Johnson Syndrome and Epidermal Necrolysis: A Delphi Consensus Exercise.
Margo Waters, Allison Dobry, Stephanie T Le, Kanade Shinkai, Thomas M Beachkofsky
JAMA Dermatology. 2023-07-01
2 citations
Rare missense variants in the SH3 domain ofare associated with hidradenitis suppurativa.
David J Morales-Heil, Li Cao, Cheryl Sweeney, Anna Malara, Frank Brown
HGG Advances. 2023-04-13
14 citations
Malignant intertrigo: A subset of toxic erythema of chemotherapy requiring recognition
Sabrina M. Smith, Philip B. Milam, Stephanie K. Fabbro, Alejandro A. Gru, Benjamin H. Kaffenberger
JAAD Case Reports. 2016-11-01

Books/Book Chapters

Dermatologic Surgery
Chapter: Dog-ear correction
Page 230 - 241Milam PB, Carr DREditors: Kantor J, Albertini JG, Bordeaux JS, Dzubow LM, Lawrence N, Miller SJ.McGraw-Hill Education, New YorkEdition 1,2018

PhilipBurkeMilamMD

Dr. Milam is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Viewing the full profile is available to verified healthcare professionals only.